oronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Varian

Autor(es)

Fumagalli, Marcilio Jorge ^[1] ; Castro-Jorge, Luiza Antunes ^[1] ; de Souza, William Marciel ^[2] ; de Azevedo, Patrick Orestes ^[3] ; Hansen, Alana Witt ^[4] ; Gazzinelli, Ricardo Tostes ^[3] ; da Fonseca, Benedito Antonio Lopes ^[1] ; Spilki, Fernando Rosado ^[4] ; Figueiredo, Luiz Tadeu Moraes ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Virol Res Ctr, Ribeirao Preto Med Sch, BR-14049900 Ribeirao Preto, SP - Brazil

^[2] Univ Texas Med Branch, World Reference Ctr Emerging Viruses & Arboviruse, Dept Microbiol & Immunol, Galveston, TX 77555 - USA

^[3] Univ Sao Paulo, Platform Translat Med Oswaldo Cruz Fdn, Ribeirao Preto Med Sch, BR-14049900 Ribeirao Preto - Brazil

^[4] Feevale Univ Novo Hamburgo, Hlthy Sci Inst, Mol Microbiol Lab, BR-93525075 Novo Hamburgo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: IRUSES-BASE; v. 14, n. 2 FEB 2022.
• Citações Web of Science: 0

Resumo

The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals. (AU)

• Processo FAPESP: 18/09383-3 - Estudo sobre epitopos de Flavivirus com importância médica no Brasil e de seus anticorpos
• Beneficiário: Marcilio Jorge Fumagalli
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 20/05527-0 - Vacina intranasal bivalente utilizando vírus influenza expressando a proteína S (spike) do SARS-CoV-2: mecanismos de proteção e lesão pulmonar
• Beneficiário: Ricardo Tostes Gazzinelli
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 19/26119-0 - Vírus emergentes e reemergentes: biologia, patogênese e prospecção
• Beneficiário: Eurico de Arruda Neto
• Modalidade de apoio: Auxílio à Pesquisa - Temático